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a b s t r a c t
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western
world, accounting for approximately 30% of all leukemias in Europe and North America.
Recently, significant progress in the characterization and understanding of the biology
and prognosis of CLL has provided new opportunities for the development of innovative,
more effective therapies. Several new anti-CD20 monoclonal antibodies directed against
lymphoid cells have been developed and are under investigation in preclinical studies
and clinical trials. Currently, the most promising is obinutuzumab, a novel third genera-
tion anti-CD20 monoclonal antibody that exhibits superior caspase-independent apopto-
sis and antibody-dependent cellular cytotoxicity than rituximab. The antibody has
shown a safety profile similar to that of rituximab and promising efficacy in patients
with CLL. The CD37 antigen may be advantageous over CD20 in diseases in which the
level of CD37 expression is higher than that of CD20. The results of recent preclinical
and early clinical studies suggest that anti-CD37 antibodies and related agents can be
useful in the treatment of CLL, and many small molecule inhibitors targeting B-cell anti-
gen receptor (BCR) signaling pathways have recently been under investigation in
patients. Promising clinical results have been observed with a Btk inhibitor, ibrutinib,
and a selective inhibitor of PI3Kd, idelalisib. Several other agents including immunomo-
dulating agents and those targeting the antiapoptotic bcl-2 family of proteins also show
promise in treating CLL. Moreover, immune-based treatment strategies intended to aug-
ment the cytotoxic potential of T cells offer exciting new treatment options for patients
with CLL.
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Chronic lymphocytic leukemia (CLL) is a B-cell malignant
disease with a progressive accumulation of B cells in the
blood, bone marrow and lymphatic tissue, and follows an
extended disease course. It is the most prevalent leukemia
in the Western World with an estimated 15, 720 new cases
in 2014 and almost 4600 attributable deaths per year in the
United States [1]. The median age at diagnosis is 72 years
and 90% of patients are older than 50 years. The diagnosis
of CLL requires the presence of at least 5000 leukemic
B lymphocytes per microliter in the peripheral blood [2]. The
management of CLL is determined by the stage and activity
of the disease, as well as age and comorbidities. Rando-
mized studies and a meta-analysis indicate that early
initiation of chemotherapy does not show benefit in CLL
and may increase mortality. There is no evidence that
cytotoxic therapy based on alkylating agents has beneficial
effects in patients with the indolent form of the disease [3].
The strategy of watchful waiting or observation, i.e. closely
monitoring patient status without giving any treatment
until progression, may be adopted [4]. However, patients
with symptomatic and/or progressive disease should be
immediately treated.
CLL is typically sensitive to a variety of cytotoxic drugs,
but the disease is considered incurable. There has been an
important increase in the range of available therapeutic
options in recent years, and many drugs are now in the
process of making the transition to the clinic [5]. The
approval of rituximab-based immunochemotherapy can be
viewed as a substantial therapeutic advance in CLL. A large
phase III randomized trial demonstrated that rituximab
combined with fludarabine and cyclophosphamide (RFC)
increased the overall response (OR) and complete response
(CR) rates, and prolonged progression free survival (PFS) and
overall survival (OS) compared with fludarabine and cyclo-
phosphamide (FC) in previously untreated and relapsed/
refractory patients [6, 7]. For the last twenty years, signifi-
cant progress in molecular and cellular biology has resulted
in a better characterization and understanding of the
biology and prognosis of CLL. These achievements have
provided new opportunities for the development of innova-
tive, more effective therapies in this disease.
Monoclonal antibodies and related agents
Several new anti-CD20 monoclonal antibodies directed
against lymphoid cells have been developed and investi-
gated in preclinical studies and clinical trials [8]. The results
of preclinical and clinical studies suggest that therapy which
uses monoclonal antibodies (mAbs) directed at a target
other than CD20 can be useful in treating CLL [9]. Such
treatments include lumiliximab (anti-CD23), epratuzumab
(anti-CD22), apolizumab (anti-MHC-II), galiximab (anti-
CD80), anti-CD40 monoclonal antibodies and TRU-016,
a small modular immunopharmaceutical (SMIP) derived
from the fusion of key domains of an anti-CD37 antibody
with a human protein.Novel anti-CD20 antibodies
Several new anti-CD20 monoclonal antibodies directed
against lymphoid cells have been developed and investigated
in preclinical studies and clinical trials [8]. Obinutuzumab
(GazyvaTM, GA-101, RO5072759, Roche) is a novel third gen-
eration monoclonal antibody which is distinct from rituximab
[10]. The antibody is based on proprietary GlycoMAb® tech-
nology, which incorporates glycoengineered antibodies that
specifically increase antibody-dependent cellular cytotoxicity
(ADCC) and thereby increase immune-mediated target cell
death, and is obtained by humanization of the parental B-Ly1
mouse antibody followed by a glycoengineering process
developed by GlycArt Biotechnology (later Roche Glycart AG).
Compared to rituximab, obinutuzumab treatment leads to 5–
100 times greater induction of ADCC, as it binds with high
affinity to the CD20 epitope, and also exhibits superior
caspase-independent apoptosis induction [11, 12]. However,
reduction in complement-dependent cytotoxicity (CDC) upon
binding to CD20 was observed. Based on this data, obinutuzu-
mab mAb is a promising therapeutic agent for CD20 positive
B-cell lymphoid malignancies, including CLL.
In a phase I/IIa study, obinutuzumab was administered as
a single agent to 24 patients, at doses from 50 to 2000 mg [13].
The antibody has shown a safety profile similar to that of
rituximab and promising efficacy in patients with CLL and
other CD20+ malignant disease, for whom no therapy of
higher priority was available [14]. The results of a large
randomized phase III trial testing three first-line chemo-
immunotherapy regimes, i.e. combined obinutuzumab and
chlorambucil, combined rituximab and chlorambucil and
chlorambucil monotherapy, in patients with comorbidities
have been recently reported (CLL11) [15, 16]. In this trial 781
patients with previously untreated CLL and a score higher
than 6 on the Cumulative Illness Rating Scale (CIRS) or an
estimated creatinine clearance of 30–69 ml per minute were
included. Treatment with obinutuzumab–chlorambucil, as
compared with rituximab–chlorambucil, resulted in higher
rates of complete response (20.7% vs. 7.0%) and molecular
response. The primary end point was investigator-assessed
PFS. Treatment with obinutuzumab–chlorambucil or rituxi-
mab–chlorambucil increased response rates and prolonged
PFS as compared with chlorambucil monotherapy. Median
PFS was 26.7 months with obinutuzumab–chlorambucil, 15.2
months for rituximab–chlorambucil, and 11.1 months for
chlorambucil alone (P < 0.001). In addition, patients treated
with obinutuzumab–chlorambucil had longer OS than those
treated with chlorambucil alone (P = 0.002). However, infu-
sion-related reactions and neutropenia were more common
in patients treated with obinutuzumab–chlorambucil than
with rituximab–chlorambucil. Obinutuzmab–chlorambucil
treatment was associated with more grade 3–4 adverse
events, mainly infusion-related reactions that occurred dur-
ing the first infusion. Infusion-related reactions were noted in
20% of patients treated with obinutuzumab–chlorambucil and
4% of patients treated with rituximab–chlorambucil. In con-
trast, the risk of infection was similar in both arms. The U.S.
Food and Drug Administration (FDA) approved obinutuzumab
for use with chlorambucil in patients with previously
untreated chronic lymphocytic leukemia [17].
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plc/Genmab A/S) is a fully human, IgG1 mAb recognizing
a different CD20 epitope to rituximab, and demonstrating
a higher cytotoxic potential than rituximab [18]. Ofatumumab
is more effective than rituximab at CDC induction and killing
target cells [19]. The close binding proximity of ofatumumab
to the cell membrane likely results in highly efficient comple-
ment deposition on B-cell membranes, without high levels of
systemic release of activated complement components [20].
Ofatumumab, in comparison to rituximab, demonstrates
greater CDC in B-cells and does not induce cell death by
apoptosis.
The results of a phase III study demonstrate that ofatumu-
mab monotherapy shows promising efficacy in heavily pre-
treated patients with fludarabine- and alemtuzumab-
refractory CLL [21]. In this study, patients received eight once-
weekly infusions of ofatumumab followed by four once-
monthly infusions during a 24-week period. The OR rates
were 58% and 47% in the fludarabine- and alemtuzumab-
refractory groups and fludarabine-refractory CLL with bulky
lymphadenopathy groups, respectively. The OR rates among
patients refractory to RFC were 50% and 44% in the fludar-
abine- and alemtuzumab-refractory groups, respectively.
Median PFS and OS times were 5.7 and 13.7 months in the
fludarabine- and alemtuzumab-refractory groups, and 5.9 and
15.4 months, respectively, in the fludarabine-refractory
patients with bulky lymphadenopathy. In 2009, the FDA
granted accelerated approval to ofatumumab for the treat-
ment of patients with fludarabine- and alemtuzumab-refrac-
tory CLL, based on a clinically meaningful and durable ORR
observed in the above trial (Hx-CD20-406). In 2010, the
European Medicines Agency (EMA) granted a conditional
marketing authorization for ofatumumab, for the treatment
of fludarabine- and alemtuzumab-refractory CLL patients.
In a recent randomized trial (Complement 1), ofatumu-
mab + chlorambucil therapy was compared with chlorambucil
alone in patients with CLL who required therapy and were
considered inappropriate for fludarabine-based therapy due
to advanced age and/or co-morbidities [22]. The results of this
study indicate that ofatumumab + chlorambucil is superior
than chlorambucil alone in this patient population. The
ofatumumab + chlorambucil arm demonstrated a higher OR
rate than the chlorambucil arm (82% vs. 69%) (P = 0.001), as
well as a superior CR rate (12% vs. 1%). PFS was also
significantly prolonged in the ofatumumab + chlorambucil
arm (22.4 months) compared to chlorambucil alone (13.1
months, P < 0.001). With a median follow-up of 29 months,
median OS was not reached for both the groups.
Anti-CD37 antibodies
CD37 is a heavily glycosylated 40–52 kDa tetraspanin trans-
membrane family protein, which consists of 4 potential
membrane-spanning regions, 2 extracellular loops and 2 short
intracytoplasmic tails [23]. This molecule may play a role in
immune cell proliferation and influences signaling via the Akt
pathway [24]. CD37 is selectively expressed on mature B cells,
with its highest expression on peripheral blood B cells. Its
significant expression was found on neoplastic cells of
patients with CLL, hairy cell leukemia and non-Hodgkin'slymphoma (NHL) [25]. The relative lineage restriction of CD37
to B cells makes it a suitable target for immunotherapy. CD37
internalizes and has modest shedding in the malignant B
cells which express it. It may be advantageous to target CD37
over CD20 in diseases in which the level of CD37 expression is
higher than that of CD20. The predominant expression of
CD37 on CLL cells makes it an ideal candidate as a therapeutic
target for treatment of CLL and has aroused great interest in
the investigation of anti-CD37 antibodies [26, 24].
The results of recent preclinical and early clinical studies
suggest that anti-CD37 antibodies can be useful in the
treatment of CLL [27]. BI 836826 (MAb 37.1) is a chimeric IgG1
type of anti-CD37 molecule which has been Fc-engineered to
improve ADCC activity and enhance affinity for Fc-gRIIIa.
Both mAb 37.1 and its humanised version, MAb 37.2, deplete
CLL cells in vitro more effectively than rituximab and alemtu-
zumab [28]. BI 836826 is under investigation in CLL in a phase
I clinical trial (ClinicalTrials.gov Identifier: NCT01296932).
Otlertuzumab (TRU-016) is produced using ADAPTIRTM
Modular Protein Technology and has shown activity in
preclinical studies and clinical trials [29]. ADAPTIR proteins
have a differentiated structure from classical mAbs and can
generate a unique signaling response. In addition, they may
mediate CDC and Fc-dependent cytotoxicity in a similar way
to mAbs. Otlertuzumab is an engineered protein that includes
anti-CD37 variable regions linked to an immunoglobulin
constant domain, produced by humanizing the precursor
agent SMIP-016, a single chain monospecific protein that
retains Fc-mediated effector functions [29, 30]. In preclinical
studies this agent was found to employ a mechanism of
apoptosis distinct from those of other agents used for CLL
treatment. In addition, otlertuzumab has demonstrated
a significantly greater ability to directly kill CLL cells than
rituximab and greater Fc-mediated cellular cytotoxicity of CLL
cells than either alemtuzumab or rituximab [31]. TRU-016 also
mediates greater NK cell mediated killing of CLL cells as
compared to either alemtuzumab or rituximab and mediates
superior direct apoptosis of CLL and other B-cell malignan-
cies. Moreover, otlertuzumab acts synergistically with bend-
amustine.
A phase I study investigated otlertuzumab in patients with
relapsed/refractory CLL or SLL [32]. TRU-016 was well toler-
ated with minimal infusional toxicity. Response occurred in
19 of 83 treated patients (23%) according to NCI-96 criteria. All
responses were partial, and occurred more commonly in
patients with symptomatic, untreated CLL. Recently, the
results of a randomized trial of otlertuzumab + bendamustine
vs. bendamustine alone were reported [33]. Patients with
relapsed CLL who had undergone 1–3 prior therapies received
otlertuzumab (20 mg/kg) weekly by i.v. infusion for two 28-
day cycles then every 14 days for four 28-day cycles, and
bendamustine (70 mg/m2) was administered i.v. on days
1 and 2 of each cycle for up to six 28-day cycles. In the control
arm, bendamustine (70 mg/m2) was given i.v. on days 1 and
2 of each cycle for up to six 28-day cycles. Among 65 patients
included in the study, 32 received otlertuzumab plus bend-
amustine and 33 were treated with bendamustine alone. The
response rate observed in patients treated with otlertuzumab
+ bendamustine was higher than that in those treated with
bendamustine alone. According to the NCI assessment, the
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with a CR rate of 48%, compared to an OR rate of 52% and
a CR rate of 9% in the bendamustine arm. No increase in
serious adverse events were noted in the otlertuzumab
+ bendamustine arm versus the bendamustine arm. A higher
rate of neutropenia was observed, but no greater rate of
infection was seen in the combination arm. Neutropenia was
noted in 50% of patients from the otlertuzumab + bendamus-
tine group and 39% in the control arm. Infections were noted
in 50% of the patients in the otlertuzumab + bendamustine
arm compared to 55% in the bendamustine arm, similarly,
pneumonia was observed in 9% and 15% of patients in the
combined and monotherapy groups, and grade 3/4 thrombo-
cytopenia was observed in 19% and 12%. These results
suggest that otlertuzumab can be a valuable drug in CLL, but
its success will depend on it demonstrating superiority over
available monoclonal antibodies and other emerging thera-
pies in achieving and sustaining CRs and improving survival.
Future phase II and III clinical trials in the development of
otlertuzumab should also evaluate combinations with che-
motherapy and/or other targeted therapies in comparison
with what is considered standard of care, especially R-FC, in
CLL patients.
The clinical development of anti-CD37 mAbs and related
agents for the treatment of CLL is challenging, and future
phase II and III clinical trials of otlertuzumab and BI 836826
in CLL patients should be informative. Although the devel-
opment of these agents into a clinically useful therapy is
probably many years away, its progress will be followedFig. 1 – Chemical structures of new small molecuwith great interest by laboratory investigators and clini-
cians.
B-cell receptor inhibitors
The use of B-cell antigen receptor (BCR) signal transduction
inhibitors also represents a promising new strategy for
targeted CLL treatment. Recently, many small molecule
inhibitors targeting BCR signaling pathways have been
under investigation in patients with CLL, including Bruton's
tyrosine kinase (Btk) inhibitors, spleen tyrosine kinase (Syk)
inhibitors and phosphatidylinositol 3-kinase-d (PI3Kd) inhibi-
tors [34]. These agents induce rapid resolution of lymphade-
nopathy and a transient increase in lymphocytosis due to
mobilization of CLL cells into the peripheral blood. BCR
inhibitors are highly active and well tolerated in CLL
patients, irrespective of high-risk genomic abnormalities
and suggest that these drugs may be an important new
targeted treatment approach for this disorder [34].
Promising clinical results have been observed with a Btk
inhibitor, ibrutinib (PCI-32765, Pharmacyclics), and
a selective inhibitor of PI3Kd, idelalisib (CAL-101, GS-1101,
Calistoga Pharmaceuticals/Gilead) (Fig. 1). These drugs are
available in oral preparations and are given as continuous
treatment. They seem to be active in traditionally poor risk
disease groups, including fluarabine-refractory patients and
patients with bulky lymphadenopathy. These drugs are part
of a promising new strategy for targeted treatment of CLLles potentially useful in the treatment of CLL
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agents induce rapid resolution of lymphadenoapathy and
a transient increase of lymphocytosis due to mobilization of
CLL cells into the peripheral blood. However, after several
months of continuous therapy, response can be achieved in
a substantial number of patients [35, 36].
Ibrutinib
Ibrutinib (PCI-32765; Imbruvica, Pharmacyclics, Inc./Johnson
& Johnson) is an irreversible covalent inhibitor of the Btk,
a critical enzyme in the BCR signaling pathway that is
essential for B-cell proliferation, survival, migration, and
tissue homing [34, 37]. It is a first-in-class, oral covalent
inhibitor of Btk designed for treatment of B-cell lymphoid
malignancies. Initial reports on the use of ibrutinib as a single
agent found that it was well-tolerated and particularly active
in patients with refractory/relapsed CLL patients. The most
common adverse reactions reported in the CLL clinical trials
were thrombocytopenia, diarrhea, bruising, neutropenia, ane-
mia, fatigue, musculoskeletal pain, rash, pyrexia, constipation
and arthralgia.
Byrd et al. conducted a phase Ib/II multicenter study to
assess the safety, efficacy, pharmacokinetics, and pharmaco-
dynamics of ibrutinib in relapsed CLL [38]. A total of 85
patients were treated with ibrutinib orally once daily, includ-
ing 51 who received 420 mg, and 34 who received 840 mg.
Ibrutinib was associated with a high frequency of durable
remissions in patients with relapsed or refractory CLL. The
OR rate was similar between patients who received 420 mg
and those who received 840 mg (71%). In addition, CR was
noted in 20% and 15% of patients, respectively. The responses
were independent of clinical and genomic risk factors noted
before treatment, including advanced-stage disease, the
number of previous therapies, and 17p13.1 deletion. At 26
months, the estimated PFS rate was 75% and the OS rate was
83%. Toxic effects included transient diarrhea, fatigue, and
upper respiratory tract infections. Hematologic toxic effects
were minimal and the patients could receive extended
therapy. O'Brien et al. assessed the safety and activity of
ibrutinib in 29 treatment-naive patients with CLL, aged 65
years and older, in open-label phase Ib/II trial [39]. After
a median follow-up of 22 months, 22 of 31 patients (71%)
achieved an objective response, including 4 CR (13%), 1 (3%)
nodular PR, and 17 (55%) PR. In 21 (68%) patients, diarrhea
was observed including grade 2 in three patients, and grade
3 in four patients.
Ibrutinib in combination with rituximab is well tolerated
and displays significant activity in high-risk CLL [40]. In updated
phase II single-center clinical trial, with a median follow-up of
14 months, 40 patients were treated with ibrutinib 420 mg p.o.
daily continuously throughout the study with rituximab
375 mg/m2 administered weekly for the first four weeks in cycle
1 and then monthly until cycle 6. Twenty patients had del17p
or TP53 mutation and 13 patients had del11q. In the updated
analysis, 34 (87%) patients achieved a PR, and three (8%) a CR,
accounting for an OR rate of 95%. The OR rate in the 20 patients
with del17p or TP53 mutation was 90%.
A combination of ibrutinib and bendamustine (BR) is also
highly active and well tolerated in patients with relapsed/refractory CLL [41]. In the study performed by Brown et al.,
30 patients with refractory/relapsed CLL and a median of
2 prior therapies received up to 6 cycles of BR with
a continuous fixed ibrutinib dose of 420 mg/day until disease
progression or toxicity. The OR rate was 93%, including
5 CRs and 3 nodular PR (nPR), and one additional patient
achieved a PR with lymphocytosis. The estimated 12 month
PFS was 90%. The most frequently reported adverse events
(AEs) were diarrhea (70%), nausea (66.7%), fatigue (46.7%),
neutropenia (40%) and upper respiratory tract infection
(36.7%). The most frequently reported grade 3 or higher AEs
were neutropenia, maculopapular rash, fatigue and throm-
bocytopenia.
A randomized, multicenter, open-label, phase III study
based on a randomized group of previously treated patients
with CLL or SLL who were not considered candidates for
treatment with purine analog-based treatments, was
initiated in June 2012 (ClinicalTrials.gov Identifier:
NCT01578707). Ofatumumab was administered over 24
weeks for 12 doses or until disease progression or unaccep-
table toxicity at 300 mg initial dose and then 2000 mg once
weekly in week 2 through 8, and then every 4 weeks on
week 12, 16, 20 and 24. Ibrutinib was given at a dose of
420 mg (3  140-mg capsules) orally once daily until disease
progression or unacceptable toxicity. After interim analysis,
the trial was stopped early because of an improvement in
PFS and OS in the ibrutinib arm. In February 2014, FDA
granted accelerated approval to ibrutinib for the treatment
of patients with CLL who have received at least one prior
therapy. The recommended dose and schedule of ibrutinib
for patients with CLL is 420 mg taken orally once daily.
However, ibrutinib will be an expensive drug. Some analysts
estimate that it will cost $98 000 a year [37].
Idelalisib
Idelalisib (CAL-101, GS-1101, Calistoga Pharmaceuticals/
Gilead) is an oral, first-in-class specific inhibitor of PI3Kd
with potent apoptotic activity against leukemic CLL cells.
PI3Kd signaling is hyperactive in many B-cell malignancies,
including CLL. Idelalisib used in monotherapy has shown
substantial clinical activity and a favorable safety profile in
heavily pretreated, refractory and high-risk patients with
CLL.
In a phase I study, patients with relapsed/refractory CLL
were treated continuously with oral idelalisib as a single
agent at a dose of 50 mg (QD or BID) [42]. The final results of
this study were recently reported [43]. Fifty-four patients
were treated continuously with single-agent idelalisib at 50–
350 mg/dose (QD or BID). The overall response rate was 56%
including 2 CR and 28 PR. The median time to first response
was 1.9 months and median PFS was 17 months. The most
common grade 3 AEs included fatigue, diarrhea, pyrexia,
rash, upper respiratory tract infection and pneumonia.
Coutre et al. report that idelalisib as a single salvage therapy
offered impressive response rates in heavily pretreated
patients with relapsed/refractory CLL [44]. Idelalisib showed
robust activity independent of high-risk features, including
del(17p)/TP53 mutation, del(11q), IGHV mutation, and
NOTCH1 mutation.
a c t a h a e m a t o l o g i c a p o l o n i c a 4 5 ( 2 0 1 4 ) 1 2 2 – 1 3 1 127Barrientos et al. presented the results of a phase I study
of idelalisib in combination with rituximab and/or bend-
amustine in patients with relapsed or refractory CLL [45].
The overall response rate was 81%, including a CR in one
patient. The median time to response was 1.9 months, and
the 2-year PFS and OS were 62% and 85%, respectively. The
most common grade 3 AEs were pyrexia, diarrhea, cough,
fatigue and nausea. These results indicate that a combina-
tion of idelalisib with rituximab and/or bendamustine is
tolerable and highly active in patients with relapsed or
refractory CLL. O'Brien et al. recently reported the results of
an up-front therapy with idelalisib and rituximab in patients
over 64 years old with CLL [46]. They were treated with
rituximab given at a dose of 375 mg/m2 weekly for 8 weeks
and idelalisib 150 mg BID continuously for 48 weeks.
Patients completing 48 weeks of treatment without progres-
sion continued to receive idelalisib on an extension study.
The overall response rate was 96% for the first 50 of the 64
enrolled patients and PFS was 91% at 24 months. Of note, all
six patients with del(17p) responded, including one with
a CR, and there have been no on-study relapses.
The results of a recently published multicenter, rando-
mized, double-blind, placebo-controlled, phase III study
indicate that a combination of idelalisib and rituximab
significantly improved OR rate, PFS and OS in patients with
relapsed CLL compared with rituximab alone [47]. The study
was stopped prematurely, after the first interim analysis,
due to the advantage of combination therapy over mono-
therapy with rituximab. Patients receiving idelalisib + ritux-
imab had OR rate 81% and those receiving rituximab alone
had OR rate 13% (P < 0.001). The median PFS was 5.5 months
in the rituximab group and was not reached in the idelali-
sib + rituximab group (P < 0.001) and overall survival at 12
months (92% vs. 80% (P = 0.02), respectively. Serious AEs
were similar in both arms and occurred in 40% of the
patients receiving idelalisib + rituximab and in 35% of those
receiving rituximab. Another phase III, randomized study
evaluating the efficacy and safety of idelalisib in combination
with bendamustine and rituximab for previously treated CLL
was initiated in June 2012 [48]. In addition, a phase III,
randomized, controlled study evaluating the efficacy and
safety of idelalisib in combination with ofatumumab for
previously treated CLL has also been initiated (NCT01659021).
Bcl-2 inhibitors
Bcl-2 proteins play a central role in enhancing cell death
activity and are thought to impact tumor formation, growth
and resistance. They are expressed at high levels in B-cell
NHL, CLL and other B-cell neoplasms. Overexpression of the
prosurvival protein Bcl-2 is a characteristic feature of many
B-lymphoid malignancies and contributes to resistance to
many commonly used chemotherapeutic agents. ABT-199
(GDC-0199, RG7601) is a novel, orally bioavailable, small
molecule with a high-affinity Bcl-2-selective BH3 mimetic,
recently developed by Abbott Laboratories [49]. This agent
specifically causes Bax/Bak-mediated apoptosis triggered
principally by the initiator BH3-only Bim protein. ABT-199
can trigger apoptosis in vitro, even in del(17p) CLL cells.Leukemic cells isolated from patients with CLL as well as
normal B-cells are also highly sensitive to ABT-199 both
in vitro and in vivo [50]. The results of an early clinical trial
show that ABT-199 has promising potential in the treatment
of CLL [51]. In contrast to the BH3 mimetic ABT-737 and the
related orally available compound ABT-263 (navitoclax),
ABT-199 is effective in prolonging the survival of immuno-
competent tumor-bearing mice and spared human platelets
in vitro and dog platelets in vivo without causing thrombocy-
topenia [52].
The results of a phase I, dose-escalation study of ABT-
199 in high-risk relapsed/refractory CLL was recently pre-
sented [53]. Cohorts received a single dose of ABT-199 on
week 1, day 3 (W1D-3) or day 7 (W1D-7), followed by
continuous once-daily dosing from W1D1, until disease
progression or unacceptable toxicity, at doses from 150 to
1200 mg. Fifty-six patients were enrolled, including 17 (38%)
with del(17p) and 18 (32%) with fludarabine-refractory dis-
ease. The OR rate was 84%, including 20% CR/CRi. Four
patients had no detectable MRD, including one patient with
fludarabine-refractory disease and del(17p) and two patients
with fludarabine refractory disease. The response rate was
82% in patients with del(17p), and 78% in patients with
fludarabine-refractory disease. Notably, 3 of the 4 patients
who had no detectable MRD and achieved a CR/CRi were
high-risk disease patients. Twenty-two patients discontin-
ued treatment: 12 due to progressive disease or other
reasons, and 8 due to AEs including diarrhea (46%), neutro-
penia (43%), fatigue (34%) and infection (29%). Grade 3/4 AEs
included neutropenia (41%), TLS (11%) and thrombocytope-
nia (10%).
Immunomodulating agents
Immunomodulating agents are a new class of drugs that
change the expression of various cytokines and costimulate
immune effector cells. Lenalidomide (Revlimid, Celgene) is
a second generation thalidomide analog with possible immu-
nomodulating and antiangiogenic properties, which may also
modulate cytokine activity in the tumor microenvironment.
Lenalidomide is orally available and has significant activity in
multiple myeloma and myelodysplastic syndrome, and most
recently it has been shown to be effective in the treatment of
various lymphoproliferative disorders such as CLL and NHL
[54]. A characteristic AE of treatment with lenalidomide in
CLL is tumor flare reaction, as well as an immune-modulatory
effect which leads to a sensation of heat and burning in the
lymph nodes. Chanan-Khan et al. investigated the antileuke-
mic effects of lenalidomide in 45 CLL patients with relapsed
or refractory disease [55]. The drug was administered orally at
a dose of 25 mg once a day for 21 days on a 28-day schedule.
Due to the occurrence of tumor lysis syndrome (TLS) in two
of the first 29 patients, the treatment protocol was revised to
allow slow dose escalation in subsequent patients, in whom
the initial dose was 5 mg, which was increased by 5 mg every
1–2 weeks to a maximum 25 mg. Twenty-nine patients were
assessable for response and all 45 patients were evaluated for
toxicity. The most common nonhematologic AEs were fatigue
(83%) and flare reaction (58%). Grade 3–4 thrombocytopenia
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in 70% of the patients. Major responses were observed in 21
patients (41%) with 4 CRs (9%) and 17 (38%) achieving a PR in
intent-to-treat analysis. The median PFS time has not been
reached.
Ferrajoli et al. report the results of a phase II study in
which lenalidomide was administered at 10 mg per day by
continuous daily dosing with dose escalation up to 25 mg,
based on patient tolerability and response [56]. Patients who
had stable disease continued treatment until disease pro-
gression. Forty-four patients with relapsed or refractory CLL
were included. Three patients (7%) achieved a CR, one
nodular PR and 10 patients a PR, at an OR rate of 32%. The
treatment was effective in 31% of the patients with high risk
cytogenetic abnormalities (del11q or del 17p), 24% of the
patients with un-mutated VH and 25% of the patients
refractory to fludarabine. Thirteen patients (30%) developed
tumor flare reaction. Despite a median dose of 10 mg daily,
significant hematologic toxicity was frequently observed.
Grade 3–4 neutropenia was noted in 41% of the courses and
grade 3–4 thrombocytopenia in 16% of the patients.
Subsequently, Andritsos et al. reported four consecutive
patients with CLL who were treated with lenalidomide and all
had serious adverse events [57]. The drug was administered
at a dose of 25 mg/day for 21 days of a 28-day cycle. Tumor
flare was observed in three patients and was characterized by
painful lymph node enlargement, with one fatal outcome.
Another patient developed sepsis and renal failure. The
efficacy of lenalidomide may be increased with the addition
of rituximab. Badoux et al. reported an OR rate of 66%
(including 12% CR) and an estimated 36-month survival of
71% in relapsed or refractory CLL patients treated with this
combination [58]. In another phase II clinical trial treatment
with lenalidomide and rituximab as the first-line therapy
induced OR in more than 90% of the patients, including an
OR rate of 53% (CR 13%) in patients with (17p) deletion [59].
The ORIGIN trial compares the safety and efficacy of
lenalidomide with those of chlorambucil in patients with
CLL, 65 years and older (NCT00910910). Interim analysis
showed higher rates of death in patients treated with
lenalidomide compared to those treated with chlorambucil,
and the recruitment for the study was stopped. Currently,
lenalidomide is under evaluation for maintenance in phase
III study in patients with CLL following first-line therapy
(CLLM1) (NCT01556776).
Autologous CD19-targeted CAR-modified T cells
Immune-based treatment strategies to augment the cytotoxic
potential of T cells offer exciting new treatment options for
patients with CLL [60]. Chimeric antigen receptors (CARs)
combine the antigen recognition domain of an antibody with
intracellular signaling domains into a single chimeric protein.
In CLL, the CD19 antigen is an ideal target for CARs since
expression is restricted to normal and malignant B cells. In
CLL patients, T cells may be genetically modified to express
CARs targeted to CD19 antigen expressed on tumor cells [61,
62]. In a pilot clinical trial, autologous T cells genetically
engineered to express an anti-CD19 CAR were used to treat3 patients with refractory CLL. In this study a lentiviral vector
expressing a chimeric antigen receptor with specificity for the
B-cell antigen CD19 was coupled with CD137 and CD3-zeta
signaling domains and autologous chimeric antigen receptor-
modified T cells were reinfused into patients [63]. Two
patients achieved a CR lasting longer than 2 years and one
patient had a stable PR.
In another study, 8 patients, including 4 with B-cell NHL
and 4 with CLL, were treated with cyclophosphamide daily for
2 days followed by fludarabine daily for 5 days and one day
after the last dose of fludarabine, received a single i.v.
infusion of anti-CD19-CAR-transduced T cells [64]. Three
hours after the T-cell administration, IL-2 infusion was
initiated. Six of the 7 evaluable obtained strictly defined
remissions. Recently, Park et al. reported a phase I clinical
trial in previously untreated CLL patients with high-risk
disease features and residual disease following the first-line
chemotherapy [65]. Patients received CD19-targeted CAR+
T cells as consolidative therapy. Autologous T cells were
collected by leukapheresis and transduced with a retroviral
vector encoding the anti-CD19 scFv linked to CD28 co-
stimulatory and CD3z signaling domains. CAR+ T cells were
infused two days after cyclophosphamide conditioning ther-
apy. Among 6 patients who received the CAR+ T cells,
2 patients who had a PR following the first-line chemotherapy
achieved a CR after the T cell infusion, 2 patients maintained
PR and 2 patients had progressive disease. Another group
recently reported the results of a study on 14 patients with
relapsed, refractory CLL treated with the CD19-targeted CAR+
T cells [66], which indicate that CAR+ T cells can induce potent
and sustained responses for patients with advanced, relapsed
and refractory CLL regardless of p53 mutation status. The
overall response rate was 57%, three patients (21%) achieved
a CR, five (36%) achieved a PR and six (43%) had no response,
for an overall major response rate of 57%. Two of 5 patients
with a PR progressed 4 months after infusion with CAR+ T,
and no patient with a CR has relapsed so far. All responding
patients developed a delayed cytokine release syndrome man-
ifested by fever, and variable degrees of nausea, anorexia,
myalgia, and transient hypotension. A randomized, phase II
dose optimization study of CAR+ T cells directed against CD19
in CLL patients with relapsed, refractory disease is ongoing [67].
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